International, multi-center, randomized, double-blind, placebo-controlled phase III study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth Disease type 1A treated 15 months

Registry ID
EUCTR2015-002378-19
Source registry
EUCTR
Status
Completed
Phase
PHASE3
Sponsor
PHARNEXT
Start date
2015-08-04
Completion date
2018-03-22
Last update
2026-08-16

Conditions

Summary

To assess the efficacy of PXT3003 compared to Placebo on the disability measured by the ONLS score in CMT1A patients treated for 15 months.

Locations

View on source registry